Targeted cell therapy for partial-thickness cartilage defects using membrane modified mesenchymal stem cells by transglutaminase 2
- 1 August 2021
- journal article
- research article
- Published by Elsevier in Biomaterials
- Vol. 275, 120994
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Intra‐articular delivery of umbilical cord‐derived mesenchymal stem cells temporarily retard the progression of osteoarthritis in a rat modelInternational Journal of Rheumatic Diseases, 2020
- Stem cell-based therapeutic strategies for cartilage defects and osteoarthritisCurrent Opinion in Pharmacology, 2018
- Advanced Therapy Medicinal Products: A Guide for Bone Marrow-derived MSC Application in Bone and Cartilage Tissue EngineeringTissue Engineering Part B: Reviews, 2018
- Mesenchymal stem/stromal cell therapy for inflammatory bowel diseaseCurrent Opinion in Gastroenterology, 2017
- Concise Review: Mesenchymal Stem Cell Therapy for Pediatric Disease: Perspectives on Success and Potential ImprovementsStem Cells Translational Medicine, 2016
- A Randomized Multicenter Trial Comparing Autologous Chondrocyte Implantation with MicrofractureJournal of Bone and Joint Surgery, 2016
- Stem Cell Therapies in Clinical Trials: Progress and ChallengesCell Stem Cell, 2015
- Autologous chondrocyte implantation: an overview of technique and outcomesAnz Journal of Surgery, 2010
- Development of Partial-thickness Articular Cartilage Injury in a Rabbit ModelClinical Orthopaedics and Related Research, 2008
- Microfracture: Surgical Technique and Rehabilitation to Treat Chondral DefectsClinical Orthopaedics and Related Research, 2001